ahlam1399
05-22-2015, 02:48 AM
Oto**my Inc?s ear drug fails mid-stage trial
May 21 (Reuters) - Drug developer Oto**my Inc said its experimental drug did **t meet the main goal of reducing the incidence of vertigo in a mid-stage trial in patients suffering from Ménière's disease.http://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/4688e88c/sc/14/mf.gif?resize=1%2C1
http://da.feedsportal.com/r/228766200334/u/49/f/654213/c/35217/s/4688e88c/sc/14/rc/1/rc.img (http://da.feedsportal.com/r/228766200334/u/49/f/654213/c/35217/s/4688e88c/sc/14/rc/1/rc.htm)
http://da.feedsportal.com/r/228766200334/u/49/f/654213/c/35217/s/4688e88c/sc/14/rc/2/rc.img (http://da.feedsportal.com/r/228766200334/u/49/f/654213/c/35217/s/4688e88c/sc/14/rc/2/rc.htm)
http://da.feedsportal.com/r/228766200334/u/49/f/654213/c/35217/s/4688e88c/sc/14/rc/3/rc.img (http://da.feedsportal.com/r/228766200334/u/49/f/654213/c/35217/s/4688e88c/sc/14/rc/3/rc.htm)
http://da.feedsportal.com/r/228766200334/u/49/f/654213/c/35217/s/4688e88c/sc/14/a2.img (http://da.feedsportal.com/r/228766200334/u/49/f/654213/c/35217/s/4688e88c/sc/14/a2.htm)
http://adchoice.feedsportal.com/r/228766200334/u/49/f/654213/c/35217/s/4688e88c/sc/14/ach.img (http://adchoice.feedsportal.com/r/228766200334/u/49/f/654213/c/35217/s/4688e88c/sc/14/ach.htm)http://pi.feedsportal.com/r/228766200334/u/49/f/654213/c/35217/s/4688e88c/sc/14/a2t.imghttp://pi2.feedsportal.com/r/228766200334/u/49/f/654213/c/35217/s/4688e88c/sc/14/a2t2.imghttp://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=lZa3e4FSSJU:z442Jtf4nVc:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=lZa3e4FSSJU:z442Jtf4nVc:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=lZa3e4FSSJU:z442Jtf4nVc:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=lZa3e4FSSJU:z442Jtf4nVc:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=lZa3e4FSSJU:z442Jtf4nVc:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/lZa3e4FSSJU
May 21 (Reuters) - Drug developer Oto**my Inc said its experimental drug did **t meet the main goal of reducing the incidence of vertigo in a mid-stage trial in patients suffering from Ménière's disease.http://i1.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/4688e88c/sc/14/mf.gif?resize=1%2C1
http://da.feedsportal.com/r/228766200334/u/49/f/654213/c/35217/s/4688e88c/sc/14/rc/1/rc.img (http://da.feedsportal.com/r/228766200334/u/49/f/654213/c/35217/s/4688e88c/sc/14/rc/1/rc.htm)
http://da.feedsportal.com/r/228766200334/u/49/f/654213/c/35217/s/4688e88c/sc/14/rc/2/rc.img (http://da.feedsportal.com/r/228766200334/u/49/f/654213/c/35217/s/4688e88c/sc/14/rc/2/rc.htm)
http://da.feedsportal.com/r/228766200334/u/49/f/654213/c/35217/s/4688e88c/sc/14/rc/3/rc.img (http://da.feedsportal.com/r/228766200334/u/49/f/654213/c/35217/s/4688e88c/sc/14/rc/3/rc.htm)
http://da.feedsportal.com/r/228766200334/u/49/f/654213/c/35217/s/4688e88c/sc/14/a2.img (http://da.feedsportal.com/r/228766200334/u/49/f/654213/c/35217/s/4688e88c/sc/14/a2.htm)
http://adchoice.feedsportal.com/r/228766200334/u/49/f/654213/c/35217/s/4688e88c/sc/14/ach.img (http://adchoice.feedsportal.com/r/228766200334/u/49/f/654213/c/35217/s/4688e88c/sc/14/ach.htm)http://pi.feedsportal.com/r/228766200334/u/49/f/654213/c/35217/s/4688e88c/sc/14/a2t.imghttp://pi2.feedsportal.com/r/228766200334/u/49/f/654213/c/35217/s/4688e88c/sc/14/a2t2.imghttp://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=lZa3e4FSSJU:z442Jtf4nVc:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=lZa3e4FSSJU:z442Jtf4nVc:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=lZa3e4FSSJU:z442Jtf4nVc:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=lZa3e4FSSJU:z442Jtf4nVc:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=lZa3e4FSSJU:z442Jtf4nVc:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/lZa3e4FSSJU